Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials

被引:0
|
作者
Lorenzetti, Lara [1 ]
Dinh, Nhi [1 ]
Whitcomb, Cason [1 ]
Martinez, Andres [1 ]
Chatani, Manju [2 ]
Lievense, Breanne [2 ]
Nhamo, Definate [3 ]
Slack, Catherine [4 ]
Eley, Natalie [1 ]
Macqueen, Kathleen [1 ]
机构
[1] FHI 360, Behav Epidemiol & Clin Sci Div, Durham, NC 27701 USA
[2] AVAC, New York, NY USA
[3] Pangaea Zimbabwe, Harare, Zimbabwe
[4] Univ KwaZulu Natal, Sch Law, Pietermaritzburg, South Africa
关键词
Meta-analysis; Biomedical HIV prevention trials; Pregnancy; Eligibility criteria; Gender transformative; DAPIVIRINE VAGINAL RING; RANDOMIZED CONTROLLED SAFETY; SEXUALLY ACTIVE WOMEN; PREEXPOSURE PROPHYLAXIS; CONTRACEPTIVE USE; DOUBLE-BLIND; MICROBICIDE GEL; SOUTH-AFRICA; MONOCLONAL-ANTIBODY; VACCINE EFFICACY;
D O I
10.1007/s10461-024-04459-z
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Historically, pregnant and lactating populations (PLP) have been excluded or disenrolled from biomedical HIV prevention trials, despite being more likely to acquire HIV during pregnancy and the post-partum period. We conducted a meta-analysis of pregnancy events in biomedical HIV prevention trials in sub-Saharan Africa to support trialists moving toward more inclusive clinical and implementation studies. We searched peer-reviewed literature reporting pregnancy events and contraceptive requirements in HIV prevention trials between 2001 and 2022. We hypothesized four variables to explain variation: contraceptive requirements, study start year, study product, and sub-region. We fit a meta-analytic model to estimate individual effect sizes and sampling variances, then conducted sub-group analyses to assess moderating effects. We identified 38 references for inclusion, across which the proportion of pregnancy events was 8% (95% confidence interval [CI]: 6-10%) with high heterogeneity (I-2 = 99%). Studies not requiring contraceptives (21%, 95%CI: 7-48%) reported a significantly higher proportion of pregnancy events than studies requiring two methods (5%, 95%CI: 2-10%). Studies launched between 2001 and 2007 (11%, 95%CI: 8-16%), microbicide gel trials (12%, 95%CI: 8-18%), and studies conducted in Western Africa (28%, 95%CI: 13-51%) reported higher proportions of pregnancy events than reference groups. Together, these variables have a moderating effect on pregnancy events (p < 0.0001), explaining 63% of heterogeneity in trials. Results describe how, over time, more stringent contraceptive requirements reduced pregnancy events, which ensured necessary statistical power but limited reproductive choice by participants. With the move toward continuing PLP on experimental products, trialists can utilize estimated pregnancy events reported here to inform strategies that accommodate participants' changing fertility preferences.
引用
收藏
页码:3850 / 3872
页数:23
相关论文
共 50 条
  • [1] Unintended Pregnancy in Women Living with HIV in Sub-Saharan Africa: A Systematic Review and Meta-analysis
    Feyissa, Tesfaye Regassa
    Harris, Melissa L.
    Melka, Alemu Sufa
    Loxton, Deborah
    AIDS AND BEHAVIOR, 2019, 23 (06) : 1431 - 1451
  • [2] Unintended Pregnancy in Women Living with HIV in Sub-Saharan Africa: A Systematic Review and Meta-analysis
    Tesfaye Regassa Feyissa
    Melissa L. Harris
    Alemu Sufa Melka
    Deborah Loxton
    AIDS and Behavior, 2019, 23 : 1431 - 1451
  • [3] The representation of gender in HIV prevention guidelines: an analysis of UNAIDS prevention policy in sub-Saharan Africa
    Merriman, C.
    HIV MEDICINE, 2020, 21 : 32 - 33
  • [4] Engaging community stakeholders in preparation for HIV Vaccine Trials Network (HVTN) 703/HIV Prevention Trials Network (HPTN) 081, an antibody mediated biomedical HIV prevention trial in sub-Saharan Africa
    Lucas, J.
    Karuna, S.
    Hinson, K.
    Sista, N.
    Yola, N.
    Ntombela, F.
    Mgodi, N.
    Luthuli, N.
    Wakefield, S.
    Andrew, P.
    Greene, E.
    Delany-Moretlwe, S.
    Gray, G.
    White, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [5] Conceptualizations of Uncertainty and Risk and Implications for Biomedical HIV Prevention Technologies in Sub-Saharan Africa: A Systematic Review
    Warren, Emily
    Paterson, Pauline
    Lees, Shelley
    Eakle, Robyn
    Stadler, Jonathan
    Larson, Heidi
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A276 - A276
  • [6] HIV infection and esophageal cancer in Sub-Saharan Africa: a comprehensive meta-analysis
    Kamsu-Tchuente, Gabriel
    Ndebia, Eugene J.
    AIDS REVIEWS, 2024, 26 (01) : 15 - 22
  • [7] Serodiscordancy and HIV prevention in sub-Saharan Africa
    Celum, Connie
    Baeten, Jared M.
    LANCET, 2013, 381 (9877): : 1519 - 1521
  • [8] Trials and Projects on Cervical Cancer and Human Papillomavirus Prevention in Sub-Saharan Africa
    Adefuye, Peter O.
    Broutet, Nathalie J.
    de Sanjose, Silvia
    Denny, Lynette A.
    VACCINE, 2013, 31 : F53 - F59
  • [9] HIV AND TROPICAL COFACTORS: LESSONS FROM THE STITREATMENT TRIALS IN SUB-SAHARAN AFRICA
    Sawers, Larry
    Stillwaggon, Eileen
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 529 - 529
  • [10] Rush to judgment: the STI-treatment trials and HIV in sub-Saharan Africa
    Stillwaggon, Eileen
    Sawers, Larry
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18